Qureight Group Secures $8.5 Million in Oversubscribed Funding Round
Qureight, a British technology company headquartered in Cambridge, has closed an oversubscribed Series A funding round, raising $8.5 million. The funding was led by Hargreave Hale AIM VCT, with contributions from XTX Ventures, Guinness Ventures, and existing investors such as Playfair Capital, Meltwind, Ascension Life Fund, and Cambridge Angels.
Key Highlights:
- Qureight specializes in developing applications and AI-driven tools that streamline data management processes for pharmaceutical companies.
- The company, founded in 2018, focuses on simplifying the handling of complex datasets typically encountered in clinical trials, especially related to lung and heart diseases.
- Qureight’s innovative system aggregates diverse health data types for in-depth analysis and offers AI-enabled 3D image simulation software.
- By leveraging these advanced tools, pharmaceutical firms can enhance their clinical trial evaluations, identify potential drug candidates, and explore new therapeutic solutions.
Industry Impact:
Techbio, an emerging player integrating technology and data in biotech, has gained significant traction due to the potential of AI in revolutionizing biotech applications, particularly in drug discovery and patient care.
Future Plans:
With the recent funding infusion, Qureight plans to focus on software development, creating cutting-edge AI-powered tools, and enhancing data consolidation efforts to further support its mission of simplifying data management for pharmaceutical entities.
For further insights, you can review the 11-slide pitch deck that played a pivotal role in securing this latest round of funding.
Qureight
Qureight
Qureight
Qureight
Qureight
Qureight
Qureight
Qureight
Qureight
Qureight
Qureight
